BioPharmSignal logoBioPharmSignal

Biotech News

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Fate Therapeutics (FATE)Fate TherapeuticsEarnings

Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN Preliminary Phase 1 clinical data presented at ASN Kidney Week 2026

Related news

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

FATEFate Therapeutics2026-10-12 11:00 EST

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

View all latest news

Fate Therapeutics

iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells. FT819 FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific...

Recent company news

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

FATEFate Therapeutics2026-11-03 21:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

FATEFate Therapeutics2026-10-12 11:00 EST

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

FATEFate Therapeutics2026-10-02 11:00 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
1.85 USD
Market cap
299.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States